Skip to content
Study details
Enrolling now

A Randomized Trial of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder

Xenon Pharmaceuticals Inc.
NCT IDNCT07172516ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

400

Study length

about 3.1 years

Ages

18–74

Locations

27 sites in AR, AZ, CA +11

About this study

This trial is testing a treatment called azetukalner versus a placebo (inactive pill) for people with bipolar depression. The goal is to see if azetukalner helps improve depressive symptoms in adults diagnosed with bipolar disorder.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Azetukalner
  • 2.Take Placebo
PhasePhase 3
Primary goalChange from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.

Secondary: Change from baseline in the Clinical Global Impression of Severity (CGI-S) score at Week 6., Change from baseline in the MADRS total score at Week 1., Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score at Week 6.

Body systems

Psychiatry / Mental Health